November 9, 2019 - Bay Street News

NASDAQ Companies - November 9, 2019

NextCure Presents Updated Clinical Data from NC318 Phase 1/2 Clinical Trial at the 34th Annual Meeting of Society for Immunotherapy of Cancer (SITC) and Announces Initiation of Phase 2 Portion of the Trial

NC318 was well toleratedSingle agent activity observed in multiple tumor types, including a CR and a PR in NSCLCInitiated Phase […]

NASDAQ Companies - November 9, 2019

New Studies Demonstrate the Predictive Value of the Vectra® Test in People Diagnosed with Rheumatoid Arthritis

SALT LAKE CITY, Nov. 09, 2019 (GLOBE NEWSWIRE) — Myriad Genetics, Inc. (NASDAQ: MYGN), a global leader in precision medicine, […]

NASDAQ Companies - November 9, 2019

Genocea Preclinical Data at SITC Demonstrate that Inhibitory Neoantigens in an Otherwise Protective Vaccine Reverse Anti-Tumor Responses

ATLAS™ identifies naturally occurring neoantigen-specific inhibitory T cell responses that are augmented after vaccinationInhibitory T cell responses exacerbate tumor growthCAMBRIDGE, […]

NASDAQ Companies - November 9, 2019

Vaccinex Presents Updated Interim Data from a Phase 1b/2 Study of Pepinemab (VX15/2503) in Combination with Avelumab (BAVENCIO®) in Non-Small Cell Lung Cancer at the 34th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

ROCHESTER, N.Y., Nov. 09, 2019 (GLOBE NEWSWIRE) — Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering novel investigational antibody […]

NASDAQ Companies - November 9, 2019

Autolus Therapeutics Presents Preclinical Data on AUT06NG at the SITC Annual Meeting

LONDON, Nov. 09, 2019 (GLOBE NEWSWIRE) — Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell […]